Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. more
Time Frame | EXEL | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.97% | -2.12% | -3% |
1-Month Return | -3.92% | -3.42% | -0.73% |
3-Month Return | 26% | -11.13% | 2.87% |
6-Month Return | 53.2% | -5.74% | 7.17% |
1-Year Return | 43.37% | 3.97% | 25.31% |
3-Year Return | 78.21% | 1.05% | 28.38% |
5-Year Return | 79.85% | 34.37% | 81.89% |
10-Year Return | 2460.77% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 967.77M | 987.54M | 1.43B | 1.61B | 1.83B | [{"date":"2019-12-31","value":52.88,"profit":true},{"date":"2020-12-31","value":53.96,"profit":true},{"date":"2021-12-31","value":78.4,"profit":true},{"date":"2022-12-31","value":88.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 33.10M | 36.27M | 52.87M | 57.91M | 72.55M | [{"date":"2019-12-31","value":45.62,"profit":true},{"date":"2020-12-31","value":50,"profit":true},{"date":"2021-12-31","value":72.88,"profit":true},{"date":"2022-12-31","value":79.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 934.68M | 951.27M | 1.38B | 1.55B | 1.76B | [{"date":"2019-12-31","value":53.18,"profit":true},{"date":"2020-12-31","value":54.12,"profit":true},{"date":"2021-12-31","value":78.63,"profit":true},{"date":"2022-12-31","value":88.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 96.58% | 96.33% | 96.32% | 96.41% | 96.04% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.74,"profit":true},{"date":"2021-12-31","value":99.73,"profit":true},{"date":"2022-12-31","value":99.82,"profit":true},{"date":"2023-12-31","value":99.44,"profit":true}] |
Operating Expenses | 565.21M | 841.21M | 1.10B | 1.35B | 1.59B | [{"date":"2019-12-31","value":35.62,"profit":true},{"date":"2020-12-31","value":53.01,"profit":true},{"date":"2021-12-31","value":69.04,"profit":true},{"date":"2022-12-31","value":85.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 369.47M | 110.06M | 286.67M | 201.48M | 170.88M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":29.79,"profit":true},{"date":"2021-12-31","value":77.59,"profit":true},{"date":"2022-12-31","value":54.53,"profit":true},{"date":"2023-12-31","value":46.25,"profit":true}] |
Total Non-Operating Income/Expense | 56.60M | 40.64M | 15.16M | 65.93M | 168.78M | [{"date":"2019-12-31","value":33.53,"profit":true},{"date":"2020-12-31","value":24.08,"profit":true},{"date":"2021-12-31","value":8.98,"profit":true},{"date":"2022-12-31","value":39.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 398.11M | 130.84M | 294.15M | 234.35M | 257.52M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":32.86,"profit":true},{"date":"2021-12-31","value":73.89,"profit":true},{"date":"2022-12-31","value":58.87,"profit":true},{"date":"2023-12-31","value":64.69,"profit":true}] |
Income Taxes | 77.10M | 19.06M | 63.09M | 52.07M | 49.76M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":24.72,"profit":true},{"date":"2021-12-31","value":81.83,"profit":true},{"date":"2022-12-31","value":67.54,"profit":true},{"date":"2023-12-31","value":64.54,"profit":true}] |
Income After Taxes | 321.01M | 111.78M | 231.06M | 182.28M | 207.76M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":34.82,"profit":true},{"date":"2021-12-31","value":71.98,"profit":true},{"date":"2022-12-31","value":56.78,"profit":true},{"date":"2023-12-31","value":64.72,"profit":true}] |
Income From Continuous Operations | 321.01M | 111.78M | 231.06M | 182.28M | 92.07M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":34.82,"profit":true},{"date":"2021-12-31","value":71.98,"profit":true},{"date":"2022-12-31","value":56.78,"profit":true},{"date":"2023-12-31","value":28.68,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 321.01M | 111.78M | 231.06M | 182.28M | 207.76M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":34.82,"profit":true},{"date":"2021-12-31","value":71.98,"profit":true},{"date":"2022-12-31","value":56.78,"profit":true},{"date":"2023-12-31","value":64.72,"profit":true}] |
EPS (Diluted) | 1.02 | 0.35 | 0.71 | 0.57 | 0.74 | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":34.31,"profit":true},{"date":"2021-12-31","value":70.1,"profit":true},{"date":"2022-12-31","value":55.88,"profit":true},{"date":"2023-12-31","value":72.55,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
EXEL | |
---|---|
Cash Ratio | 3.02 |
Current Ratio | 3.93 |
Quick Ratio | 3.88 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
EXEL | |
---|---|
ROA (LTM) | 12.81% |
ROE (LTM) | 20.20% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
EXEL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.23 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.77 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
EXEL | |
---|---|
Trailing PE | 21.76 |
Forward PE | 21.79 |
P/S (TTM) | 4.62 |
P/B | 4.23 |
Price/FCF | 37 |
EV/R | 4.14 |
EV/Ebitda | 13.56 |
PEG | 2.27 |
Exelixis Inc (EXEL) share price today is $33.29
Yes, Indians can buy shares of Exelixis Inc (EXEL) on Vested. To buy Exelixis Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EXEL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Exelixis Inc (EXEL) via the Vested app. You can start investing in Exelixis Inc (EXEL) with a minimum investment of $1.
You can invest in shares of Exelixis Inc (EXEL) via Vested in three simple steps:
The 52-week high price of Exelixis Inc (EXEL) is $36.97. The 52-week low price of Exelixis Inc (EXEL) is $19.2.
The price-to-earnings (P/E) ratio of Exelixis Inc (EXEL) is 21.729
The price-to-book (P/B) ratio of Exelixis Inc (EXEL) is 4.23
The dividend yield of Exelixis Inc (EXEL) is 0.00%
The market capitalization of Exelixis Inc (EXEL) is $9.62B
The stock symbol (or ticker) of Exelixis Inc is EXEL